LRP1B and non-small cell lung carcinoma: Previous studies reported that LRP1B mutations were associated with worse prognosis of hepatocellular carcinoma based on analyses of TCGA and Chinese cohorts [46,47], but a higher TMB and better immunotherapy outcome in NSCLC [36].